Fig. 5: Activities of MYC and NME2 are associated with poor response to Enzalutamide.

a, b Comparing NME2 TR and MYC pathway activity between adenocarcinoma cells (dark magenta) and other cells (dark orchid) in neoadjuvant and adjuvant samples of a CRPC patient obtained from He et al. P value was estimated using a one-tailed Welch t-test. In boxplots, the center line corresponds to the median and the box limits correspond to the first and third quartiles (the 25th and 75th percentiles). The upper and lower whiskers extend to the maximum or minimum value within 1.5 times the interquartile range, respectively. c (Left, top) Pearson correlation analysis between NME2 TR and MYC pathway activity in the Abida et al. cohort subjected to adjuvant Enzalutamide. Pearson r and p value are indicated. (Left, bottom) Patients with high-MYC and high-NME2 (yellow) and the rest of the patients (blue) were identified. (Right) Kaplan-Meier survival analysis, comparing high-MYC and high-NME2 group (yellow) to the rest of the patients (blue) in Abida et al. cohort subjected to adjuvant Enzalutamide. Log-rank p value, adjusted HR (hazard ratio), and CI (confidence interval) are indicated. d (Left, top) Pearson correlation analysis between NME2 TR and MYC pathway activity in SU2C West Coast cohort subjected to Enzalutamide and/or Abirterone either before or after sample collection. Pearson r and p value are indicated. (Left, bottom) Patients with high-MYC and high-NME2 (yellow) and the rest of the patients (blue) were identified. (Right) Kaplan-Meier survival analysis, comparing high-MYC and high-NME2 group (yellow) to the rest of the patients (blue) in SU2C West Coast cohort. Log-rank p value, adjusted HR (hazard ratio), and CI (confidence interval) are indicated.